The Food and Drug Administration has approved the first-ever Ebola vaccine called Ervebo in the US. Ervebo, the vaccine for Ebola virus disease has been developed by Merck & Co. The vaccine is suitable for 18 years old individuals and above. It is the first Ebola drug, which has been approved by the FDA. Ervebo vaccine has been approved by the European Commission as well in November this year. The vaccine had been proved to be 100 percent effective in preventing Ebola during the West Africa outbreak during 2014 and 2016. It is given in a single dose injection form to the people. The World Health Organization (WHO) had used the vaccine in 2018 to fight World’s second-largest Ebola outbreak. WHO gave it the status of the first prequalified Ebola vaccine to provide countries speedy access to the vaccine.
The deadly disease is transmitted through direct contact with blood, body fluids, and tissues of infected people. It can also spread through contaminated surfaces and materials with the virus. Fever, fatigue, muscle pain, headache, and sore throat are common symptoms of the Ebola virus disease. Symptoms of the disease might appear within two days of the infection. However, these symptoms can take up to 21 days to show up after exposure to the deadly virus. Vomiting, diarrhea, kidney issues, liver issues, rash, and bleeding are some severe symptoms of the ailment. After many studies in the safety of the drug, the FDA awarded it the status of the Breakthrough Therapy Designation for developing the vaccine. Secretary of Health and Human Services has termed the new vaccine as a victory of American global health leadership.
The rate of Ebola incidents in the US is quite low. However, the government is committed to combat the dreaded disease in Africa and an ongoing outbreak in the Democratic Republic of Congo. More than 258000 people have been given the Ebola vaccine in DR Congo during the current outbreak. Ervebo has been 97 percent effective in the region. The new vaccine is supposed to be available in the third quarter of 2020. Merck, the manufacturer of the drug is working seamlessly with the US government, UNICEF, and WHO to evaluate the efficiency of the drug in the future of public health care and response efforts against Ebola.